Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease: a Randomised, Double-blind, Controlled Study
Authors not listed
Federal University of Minas Gerais · 2013
Abstract
We aim to evaluate the safety and efficacy of repetitive transcranial magnetic stimulation (rTMS) for apathy treatment in patients with Alzheimer's disease (AD). We hypothesize that rTMS will be superior to placebo to reduce apathy symptoms and severity in patients with AD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2013). Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease: a Randomised, Double-blind, Controlled Study. <em>Federal University of Minas Gerais</em>. https://clinicaltrials.gov/study/NCT01885806
Vancouver
Anonymous. Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease: a Randomised, Double-blind, Controlled Study. Federal University of Minas Gerais. 2013.
BibTeX
@misc{anon2013Repeti,
title = {Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease: a Randomised, Double-blind, Controlled Study},
author = {Anonymous},
journal = {Federal University of Minas Gerais},
year = {2013},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Ali Rezai 2019
Open access · US-GOV
Application of Transcranial Magnetic Stimulation Coupled With Virtual Reality for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2000
Open access · US-GOV
Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2001
Open access · US-GOV
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
Avanir Pharmaceuticals 2012
Open access · US-GOV
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Tel-Aviv Sourasky Medical Center 2008
Open access · US-GOV
Phase 2 (Feasibility) Study of Transcranial Magnetic Stimulation as Additional Therapy to Drug Treatment in Patients With Alzheimer's Disease
Memory Pharmaceuticals 2005
Open access · US-GOV